Magenau, J <br/><br/>
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.  [electronic resource] 

 -  Bone marrow transplantation  Jan 2017 
 - 59-65 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1476-5365 
<br/><br/><label>Standard No.: </label>10.1038/bmt.2016.188  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine Nucleotides--administration & dosage<br/>Adult<br/>Aged<br/>Allografts<br/>Arabinonucleosides--administration & dosage<br/>Busulfan--administration & dosage<br/>Clofarabine<br/>Disease-Free Survival<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Induction Chemotherapy<br/>Leukemia, Myeloid, Acute--mortality<br/>Male<br/>Middle Aged<br/>Survival Rate<br/>Transplantation Conditioning